Advanced Cancer
14 competing products in clinical development for Advanced Cancer.
Pipeline by Phase
Phase 111
Phase 1/21
Phase 32
All Products (14)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| T-DXd | Daiichi Sankyo | Phase 3 | Recruiting | 47 |
| Nivolumab | Ono Pharmaceutical | Phase 3 | Completed | 40 |
| AK-105 | Akeso | Phase 1 | Completed | 29 |
| pegfilgrastim + LY2523355 | Eli Lilly | Phase 1 | Completed | 29 |
| [¹⁴C]Prexasertib + Prexasertib | Eli Lilly | Phase 1 | Completed | 29 |
| CS-7017 | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Lirilumab + Nivolumab + Ipilimumab | Ono Pharmaceutical | Phase 1 | Completed | 29 |
| NKTR-214 + Nivolumab | Ono Pharmaceutical | Phase 1 | Completed | 29 |
| OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib | OnKure Therapeutics | Phase 1 | Recruiting | 26 |
| LY3200882 + Pembrolizumab | Eli Lilly | Phase 1/2 | Withdrawn | 24 |
| LY3434172 | Eli Lilly | Phase 1 | Terminated | 21 |
| DS-9606a | Daiichi Sankyo | Phase 1 | Terminated | 21 |
| Lenvatinib + Capecitabine | Eisai | Phase 1 | Withdrawn | 21 |
| [14C]-Nanatinostat + Nanatinostat (free base) tablets in combination with Valganciclovir + Nanatinostat mesylate tablets in combination with Valganciclovir + Single-agent Nanatinostat (free base) tablets | Viracta Therapeutics | Phase 1 | Terminated | 11 |